- Principal Investigator/s: Prof Mary Ward
- Name of the Study: Intervention with Riboflavin to improve Vascular health and ENdothelial functioning in Genetically at- risk adults (InteRVENE study)
- Why is this Study important? Around 10% of the world’s population have a particular genetic make-up (known as the TT genotype) that may increase the risk of having high blood pressure (hypertension). Our research group has previously reported that a B-vitamin riboflavin can decrease blood pressure in adults with this genetic risk. Whether B-vitamins can also improve blood vessel function, an important predictor of cardiovascular health is not known. Also, the effects of short-term (4 and 8 weeks) riboflavin supplementation and different riboflavin doses on blood pressure and blood vessel function is not known.
- What is the Research question/aim?: This study aims to examine whether riboflavin supplementation at different doses can lower blood pressure and improve blood vessel function in adults screened for the TT genotype.
- What the Study involves: This study will last for 16 weeks, with four separate study visits at weeks 0, 4, 8 and 16. Each participant will be asked to complete a survey which includes life and health style questionnaire as well as the International Physical Activity Questionnaire (IPAQ).
- PPI Involvement: We routinely engage with our participants to disseminate results and to get input on practical aspects of study design. Our PPI group also provide valuable feedback on out participant information sheets.
- Who can take part in the Study? This study aims to recruit Male adults between the ages of 18 and 60 who are not currently taking B-vitamin supplement who have had their MTHFR genotype sequenced from a previous research study.
- Contact Information:
Researcher: Ryan Barlow
PI: Professor Mary Ward